Osteoarthritis and joint pain relief
Multiple RCTs demonstrate Boswellia extract significantly reduces joint pain, stiffness, and improves physical function in knee osteoarthritis patients within 7–30 days. Meta-analyses confirm consistent efficacy across trials, with effect sizes comparable to NSAIDs but without gastrointestinal toxicity.
Anti-inflammatory via 5-LOX inhibition
AKBA is a potent, selective inhibitor of 5-lipoxygenase (5-LOX) — the enzyme that produces pro-inflammatory leukotrienes (LTB4). Unlike NSAIDs which inhibit COX enzymes, Boswellia targets the leukotriene pathway, providing complementary anti-inflammatory action with no GI ulceration risk.
Inflammatory bowel disease
Clinical trials show Boswellia extract is comparable to sulfasalazine and mesalazine for maintaining remission in Crohn's disease and ulcerative colitis. The 5-LOX-leukotriene pathway is particularly important in IBD pathophysiology, explaining Boswellia's specific efficacy in gut inflammation.
Asthma and respiratory inflammation
A double-blind RCT showed Boswellia (300 mg three times daily) reduced asthma attack frequency by 70% and improved lung function (FEV1, peak flow) in 40 patients — with 70% of treated patients showing significant improvement vs. 27% placebo. Leukotriene inhibition reduces bronchospasm.
Cancer-supportive anti-inflammatory
Boswellic acids inhibit NF-κB, reduce tumor necrosis factor, and modulate topoisomerase I and II (DNA repair enzymes involved in cancer cell proliferation). Used in integrative oncology particularly for brain tumor management alongside conventional therapy.
5-LOX selective inhibition
AKBA non-competitively inhibits 5-lipoxygenase with IC50 values in the low micromolar range, preventing conversion of arachidonic acid to 5-HPETE and subsequently to LTA4 and pro-inflammatory leukotrienes (LTB4, LTC4, LTD4). This pathway is distinct from and complementary to COX inhibition by NSAIDs.
MMP-3 matrix metalloprotease inhibition
AKBA inhibits matrix metalloprotease-3 (MMP-3, stromelysin), the enzyme responsible for degrading articular cartilage collagen and proteoglycans. This cartilage-protective mechanism explains why Boswellia improves joint structure and reduces cartilage space narrowing in addition to reducing pain.
NF-κB and cytokine modulation
Boswellic acids inhibit IκB kinase (IKK) activity, preventing NF-κB nuclear translocation and downstream expression of TNF-α, IL-1β, IL-6, and other pro-inflammatory cytokines. This central inflammatory pathway inhibition explains Boswellia's broad anti-inflammatory effects across multiple tissue types.
Systematic review and meta-analysis of 7 RCTs examining Boswellia serrata extract for knee osteoarthritis.
Pooled data from 7 RCTs including 545 osteoarthritis patients.
Boswellia significantly reduced pain (SMD -0.57), improved physical function (SMD 0.43), and reduced morning stiffness vs. placebo. Effect size comparable to NSAIDs without GI adverse effects. All 7 trials showed positive results.
RCT comparing Boswellia resin (1,200 mg/day) vs. sulfasalazine (3,000 mg/day) in 102 patients with active Crohn's disease for 8 weeks.
102 active Crohn's disease patients. 8-week parallel design.
Boswellia and sulfasalazine produced equivalent improvements in Crohn's Disease Activity Index (CDAI). Boswellia induced remission in 44% vs. 42% sulfasalazine. Superior tolerability profile. Supports Boswellia as comparable to sulfasalazine for Crohn's disease.
Double-blind RCT of Boswellia (300 mg three times daily) vs. placebo in 40 asthma patients for 6 weeks.
40 adults with bronchial asthma. 6-week intervention.
70% of Boswellia patients showed significant improvement (reduced attack frequency, improved FEV1 and peak flow) vs. 27% placebo. Significant reduction in serum eosinophils and ESR. Supports leukotriene-targeting mechanism for asthma.